Bolt Biotherapeutics, Inc.
BOLT
$3.68
-$0.18-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.70M | 6.50M | 7.70M | 5.20M | 4.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.70M | 6.50M | 7.70M | 5.20M | 4.17M |
| Cost of Revenue | 21.26M | 23.61M | 28.22M | 34.95M | 42.20M |
| Gross Profit | -16.56M | -17.11M | -20.52M | -29.75M | -38.03M |
| SG&A Expenses | 11.67M | 12.77M | 13.80M | 14.63M | 15.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.18M | 36.62M | 42.33M | 49.89M | 57.60M |
| Operating Income | -28.48M | -30.12M | -34.63M | -44.70M | -53.44M |
| Income Before Tax | -28.74M | -29.58M | -33.38M | -42.68M | -50.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.74 | -29.58 | -33.38 | -42.68 | -50.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.74M | -29.58M | -33.38M | -42.68M | -50.71M |
| EBIT | -28.48M | -30.12M | -34.63M | -44.70M | -53.44M |
| EBITDA | -27.56M | -29.02M | -33.34M | -43.24M | -51.83M |
| EPS Basic | -16.44 | -16.34 | -17.78 | -22.27 | -26.48 |
| Normalized Basic EPS | -9.44 | -9.67 | -10.58 | -13.51 | -16.14 |
| EPS Diluted | -16.44 | -16.34 | -17.78 | -22.27 | -26.48 |
| Normalized Diluted EPS | -9.44 | -9.67 | -10.58 | -13.51 | -16.14 |
| Average Basic Shares Outstanding | 7.02M | 7.24M | 7.48M | 7.67M | 7.66M |
| Average Diluted Shares Outstanding | 7.02M | 7.24M | 7.48M | 7.67M | 7.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |